Topoisomerase II is the target for several highly active anticancer drugs that induce cell death by enhancing enzyme-mediated DNA scission. Although these agents dramatically increase levels of nucleic acid cleavage in a site-specific fashion, little is understood regarding the mechanism by which they alter the DNA site selectivity of topoisomerase II. Therefore, a series of kinetic and binding experiments were carried out to determine the mechanistic basis by which the anticancer drug, etoposide, enhances cleavage complex formation at 22 specific nucleic acid sequences. In general, maximal levels of DNA scission (i.e. C max ) varied over a considerably larger range than did the apparent affinity of etoposide (i.e. K m ) for these sites, and there was no correlation between these two kinetic parameters. Furthermore, enzyme⅐drug binding and order of addition experiments indicated that etoposide and topoisomerase II form a kinetically competent complex in the absence of DNA. These findings suggest that etoposide⅐ topoisomerase II (rather than etoposide⅐DNA) interactions mediate cleavage complex formation. Finally, rates of religation at specific sites correlated inversely with C max values, indicating that maximal levels of etoposide-induced scission reflect the ability of the drug to inhibit religation at specific sequences rather than the affinity of the drug for site-specific enzyme-DNA complexes.Topoisomerase II is an enzyme that decatenates and disentangles DNA by passing one DNA helix through another (1-5). Due to the requirement for such a DNA strand passage activity in a number of critical nuclear processes, including replication, recombination, and chromosome segregation (1, 3, 4, 6 -10), topoisomerase II is essential for the survival of proliferating eukaryotic cells (11)(12)(13)(14).As a prerequisite for its DNA passage reaction, topoisomerase II generates transient double-stranded breaks in the nucleic acid backbone (3-5). In order to maintain the integrity of the cleaved genetic material during this process, the enzyme forms a proteinaceous bridge that spans the nucleic acid break. This bridge is anchored by covalent phosphotyrosyl bonds established between the active site residues of the homodimeric enzyme and the newly created 5Ј-DNA termini (15-18). Because the covalent topoisomerase II-cleaved DNA complex (referred to as the cleavage complex) is normally a short-lived intermediate in the catalytic cycle of the enzyme, it is tolerated by the cell. However, when present in high concentrations, cleavage complexes become potentially toxic, promoting frameshift mutations, permanent double-stranded DNA breaks, illegitimate recombination, and apoptosis (6, 8, 19 -23).The cytotoxic potential of topoisomerase II has been exploited clinically by the development of anticancer drugs that generate high levels of covalent enzyme-DNA cleavage complexes (19,(22)(23)(24)(25)(26). Because rapidly proliferating cells contain high concentrations of topoisomerase II (27-31), aggressive malignancies are most susceptibl...
The mitogen-activated protein (MAP) kinases, extracellular signal-related kinase 1 (ERK1) and ERK2, regulate cellular responses by mediating extracellular growth signals toward cytoplasmic and nuclear targets. A potential target for ERK is topoisomerase II␣, which becomes highly phosphorylated during mitosis and is required for several aspects of nucleic acid metabolism, including chromosome condensation and daughter chromosome separation. In this study, we demonstrated interactions between ERK2 and topoisomerase II␣ proteins by coimmunoprecipitation from mixtures of purified enzymes and from nuclear extracts. In vitro, diphosphorylated active ERK2 phosphorylated topoisomerase II␣ and enhanced its specific activity by sevenfold, as measured by DNA relaxation assays, whereas unphosphorylated ERK2 had no effect. However, activation of topoisomerase II was also observed with diphosphorylated inactive mutant ERK2, suggesting a mechanism of activation that depends on the phosphorylation state of ERK2 but not on its kinase activity. Growth and differentiation factors regulate the mitogenactivated protein kinases (MAPKs), extracellular signal-related kinase 1 (ERK1) and ERK2, through pathways utilizing receptor tyrosine kinases, cytokine receptors, and heterotrimeric G protein-coupled receptors (for a review, see reference 33). Activation occurs by coupling of receptors to Ras, Raf-1, and MAPK kinase 1 (MKK1) or MKK2, the latter of which activates ERK directly through phosphorylation at regulatory threonine and tyrosine residues. In response to phosphorylation, ERK translocates to nuclei, an event which has been shown to involve phosphorylation and dimerization of this kinase, although enhancement of its specific activity is not required (23). Nuclear uptake of ERK is strongly correlated with proliferation of fibroblasts and neuronal differentiation of PC12 cells (52, 54); thus, the identification of nuclear substrates for this enzyme is an important goal in elucidating mechanisms for biological control.The MKK/ERK pathway has an essential role in promoting S phase entry, through the phosphorylation of nuclear transcription factors such as Elk/p62TCF, induction of immediateearly genes such as Fos and Egr-1, and transcriptional upregulation of cyclin D1 (3, 30, 31). In contrast, targets for MKK or ERK in somatic cell mitosis are less well defined. MKK and ERK are activated within nuclei during prophase (48, 60), indicating that this pathway may also promote early mitotic events. This is consistent with results suggesting that ERK inactivates the chromatin remodeling activity of the hSWI-SNF complex, an event necessary for mitotic chromosome condensation (50).DNA topoisomerase II is an important constituent of chromatin, functioning primarily in chromosome condensation and sister chromatid separation during mitosis, with possible secondary functions in transcription and DNA replication (39,55). It is the segregation of newly replicated daughter chromosomes that renders topoisomerase II essential to the survival of eukary...
Although a number of drugs currently in use for the treatment of human cancers act by stimulating topoisomerase II-mediated DNA breakage, little is known regarding interactions between these agents and the enzyme. To further define the mechanism of drug action, interactions between ellipticine (an intercalative drug with clinical relevance) and yeast topoisomerase II were characterized. By utilizing a yeast genetic system, topoisomerase II was identified as the primary cellular target of the drug. Furthermore, ellipticine did not inhibit enzyme-mediated DNA religation, suggesting that it stimulates DNA breakage by enhancing the forward rate of cleavage. Finally, ellipticine binding to DNA, topoisomerase II, and the enzyme-DNA complex was assessed by steady-state and frequency domain fluorescence spectroscopy. As determined by changes in fluorescence intensity and emission maximum wavelength, and by lifetime analysis, only the protonated species of ellipticine bound to a double-stranded 40-mer oligonucleotide containing a topoisomerase II cleavage site (KD approximately 65 nM). In contrast, predominantly deprotonated ellipticine bound to the enzyme.DNA complex (KD approximately 1.5 microM) or to the enzyme in the absence of nucleic acids (KD approximately 160 nM). These findings suggest that ellipticine interacts directly with topoisomerase II and that the enzyme dictates the ionic state of the drug in the ternary complex. A model is presented in which the topoisomerase II.ellipticine.DNA complex is formed via initial drug binding to either the enzyme or DNA.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.